Quest for discovering novel CDK12 inhibitor.

CDK12 is essential for cellular processes like RNA processing, transcription, and cell cycle regulation, inhibiting cancer cell growth and facilitating macrophage invasion. CDK12 is a significant oncogenic factor in various cancers, including HER2-positive breast cancer, Anaplastic thyroid carcinoma, Hepatocellular carcinoma, prostate cancer, and Ewing sarcoma. It is also regarded as a potential biomarker, emphasizing its broader significance in oncology.

Prevalence of Back and Neck Pain Among Orthopedic Surgeons in Riyadh, Saudi Arabia.

Background And Objectives: Orthopedic surgeons' demanding work may negatively affect their health. This study examines the prevalence of musculoskeletal (MSK) issues, specifically back and neck pain, among orthopedic surgeons in Riyadh, Saudi Arabia, and explores contributing sociodemographic factors.

Materials And Methods: We conducted an observational study that assessed the prevalence of back and neck pain among certified orthopedic surgeons using an online survey, which included Logistic regression for risk factors, one-way ANOVA for disability-contributing factors, and Tukey's post-hoc test for subgroup analysis.

New frontiers in multicomponent mechanosynthesis for organic molecules: modern marvels.

In the past, mechanochemical approaches in organic synthesis were largely overlooked, but their perception within the synthetic community has shifted in recent years, marking a trend toward becoming mainstream. Mechanochemical multicomponent organic synthesis has garnered significant interest from both the academic and industrial chemical sectors. The efficiency and environmental friendliness of procedures conducted through mechanical activation have established mechanical procedures as prominent green techniques.

Trastuzumab-Induced Early Corneal Melt in HER2-Positive Breast Cancer: A Case Report and Review.

BACKGROUND Trastuzumab (Herceptin) is a recombinant DNA-derived humanized monoclonal antibody that the US Food and Drug Administration (FDA) approved in 1998 for metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer therapy. It selectively binds to the extracellular domain of HER2 and mediates an antibody-dependent cellular toxicity in various tissues. Trastuzumab use alone does not typically cause aggressive ocular complications.